Keros Therapeutics hits all-time low as safety concerns halt trial dosing

Keros Therapeutics

12/12/2024 15:09

(Updates)
    ** Shares of drug developer Keros Therapeutics  KROS.O  fall
~77% to its lowest level of $15.96 since its Nasdaq debut in
April 2020
    ** KROS says it has halted dosing of 3.0 mg per kg and 4.5
mg per kg doses of its high blood pressure treatment in a
mid-stage study due to fluid buildup around the heart
    ** Dosing in the 1.5 mg/kg arm will continue after a
risk-benefit review by an independent monitoring committee -
KROS
    ** Co has notified the U.S. FDA about it and expects to
present data from all treatment arms in Q2 2025 - KROS
    ** Including session's moves, stock has fallen 58.6% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))